Collective results from the SAKURA phase 3 clinical trial program investigating daxibotulinumtoxinA for injection for the treatment of moderate-to-severe glabellar lines show that the neuromodulator provides generally safe and long-lasting results.
Menlo and Foamix announces shareholders have voted to approve the proposed merger between the two companies. Anticipated finalization of the merger is March 2020.
Gene expression profile (GEP) testing outcomes have positively impacted the management decision-making process for cutaneous squamous cell carcinoma (cSCC), according to a recent study.
Susan C. Taylor, M.D., shares distinguishing characteristics of differential diagnoses to keep in mind when examining skin of color patients for rosacea.
It's thought that rosacea affects about 10% of the population, but this estimation may not be completely accurate as the condition is often underdiagnosed – especially in individuals with darker skin types.
Positive results from a study investigating non-thermal Nano-Pulse Stimulation as a treatment for cutaneous non-genital warts have led to a larger multicenter study that is looking to optimize treatment parameters and hopefully replicate the early evidence of its efficacy and safety.
A wearable patch may soon be able to assess inflammatory biomarkers found in the sweat and interstitial fluid in individuals with atopic dermatitis to ultimately provide real-time information about their skin health.
It’s known that combination therapies can be used to create ideal treatment outcomes, but according to Dr. Suneel Chilukuri, results may also last longer than originally thought.
Platelet-rich plasma (PRP) shows promise as an adjunctive treatment for atrophic acne scarring, but experts say more research is needed.
Sol-Gel announces updates to their drug pipeline and their goals for 2020, which include submitting multiple provisional patents and NDAs for the treatment of a variety of skin conditions.